Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TL 938

Next Previous
Drug Profile

TL 938

Alternative Names: TL-938

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Teligene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 10 Dec 2024 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
  • 27 Sep 2024 Suzhou Teligene initiates a phase Ib trial for HER2-positive solid tumours in China, prior to September 2024 (Suzhou Teligene pipeline, September 2024)
  • 19 Sep 2024 Suzhou Teligene plans a phase II trial for Colorectal cancer (Combination-therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in October 2024 (PO, Capsule) (NCT06589830)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top